Baylor College of Medicine

Neurology: Case of the Month - Baylor College of Medicine

Patient #11 emphasizes the importance of the differential diagnosis of a patient with a rapidly progressive dementia. According to the family, the patient was normal until three months prior to ...
Medscape

Central Nervous System Tumors

From 1950 to 1989, 6338 cases could be grouped according to their CNS tumors based on our crude classification. Among these cases, 3530 were male, 2734 were female, and 935 were children and teenagers ...
ascopubs.org

Temozolomide-based chemoradiation in naïve pure and mixed anaplastic astrocytoma: Long term results of a phase II study.

Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. Background: This phase II study was performed to assess survival, local control and toxicity using ...
ascopubs.org

Impact of extent of surgical resection on survival outcomes in patients with IDH-mutant anaplastic astrocytomas and IDH mutant anaplastic oligodendrogliomas: A SEER database study.

Detection of methylated MGMT using radiomic imaging: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
Nasdaq

Mustang Bio Announces FDA Orphan Drug Designation for MB-101 in Treatment of Recurrent Glioblastoma and High-Grade Astrocytomas

Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
Cure Today

FDA Grants Orphan Drug Status to MB-101 for Glioblastoma, Astrocytomas

MB-101 received orphan drug designation for treating recurrent diffuse astrocytomas and glioblastoma, supporting rare disease treatments affecting fewer than 200,000 people in the U.S. Combining ...